TECX

+ Watchlist + Portfolio

Tectonic Therapeutic, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $22.67
52-Week Range: $14.60 – $39.53
Market Cap: $440.64M
P/E (TTM): —
EPS (TTM): -4.57
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.84
PEG Ratio: —
Return on Equity: -33.80%
Return on Assets: -22.29%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 22.29
Debt/Equity: 0.02
Total Debt: $4.40M
Free Cash Flow: $-46.72M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $217.97M

TECX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$25.65M	$36.97M	$41.36M	$63.49M
Selling, General & Admin	$7.18M	$7.68M	$16.65M	$20.55M
Operating Expenses	$32.83M	$44.65M	$58.02M	$84.04M
Operating Income	-$32.83M	-$44.65M	-$58.02M	-$84.04M
EBITDA	-$31.03M	-$41.19M	-$56.23M	-$71.48M
Pretax Income	-$32.18M	-$42.82M	-$57.98M	-$72.92M
Income Tax	—	—	$0.00	$1.23M
Net Income	-$32.18M	-$42.82M	-$57.98M	-$74.15M
Diluted EPS	-2.18	-2.91	-6.83	-4.05
Diluted Shares	14.73M	14.73M	8.49M	18.32M

TECX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$35.97M	$28.77M	$141.24M	$253.80M
Current Assets	$37.04M	$30.88M	$146.86M	$257.36M
Total Assets	$47.21M	$39.40M	$152.91M	$261.04M
Current Liabilities	$7.84M	$40.89M	$11.61M	$9.67M
Total Debt	$5.79M	$4.34M	$3.30M	$1.28M
Total Liabilities	$92.86M	$124.03M	$12.13M	$9.71M
Retained Earnings	-$47.78M	-$90.60M	-$148.59M	-$222.74M
Shareholders' Equity	-$45.65M	-$84.64M	$140.78M	$251.33M
Working Capital	$29.20M	-$10.00M	$135.25M	$247.69M

TECX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$27.64M	-$40.68M	-$59.08M	-$60.08M
Capital Expenditure	-$2.09M	-$279.00K	-$156.00K	-$208.00K
Free Cash Flow	-$29.73M	-$40.96M	-$59.24M	-$60.29M
Depreciation & Amortisation	$1.01M	$1.48M	$1.65M	$1.38M
Stock-Based Compensation	$1.12M	$1.12M	$3.49M	$10.50M
Investing Cash Flow	-$2.09M	-$279.00K	-$156.00K	-$138.00K
Financing Cash Flow	$37.63M	$33.75M	$171.71M	$173.35M
Net Change in Cash	$7.90M	-$7.21M	$112.48M	$113.14M

TECX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$13.04M	$17.18M	$16.93M	$16.34M	$20.87M	$18.05M
Selling, General & Admin	$5.26M	$5.15M	$4.96M	$5.17M	$6.43M	$6.17M
Operating Expenses	$18.30M	$22.33M	$21.89M	$21.52M	$27.30M	$24.22M
Operating Income	-$18.30M	-$22.33M	-$21.89M	-$21.52M	-$27.30M	-$24.22M
EBITDA	-$15.53M	-$18.65M	-$18.68M	-$18.63M	-$24.93M	-$21.92M
Pretax Income	-$15.91M	-$19.01M	-$19.04M	-$18.97M	-$25.24M	-$22.21M
Income Tax	—	$976.00K	$0.00	$254.00K	—	$77.00K
Net Income	-$15.91M	-$19.98M	-$19.04M	-$19.23M	-$25.24M	-$22.29M
Diluted EPS	-0.93	-1.07	-1.02	-1.03	-1.34	-1.18
Diluted Shares	17.16M	18.68M	18.71M	18.72M	18.77M	18.96M

TECX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$306.25M	$287.38M	$268.44M	$253.80M	$236.89M	$227.07M
Current Assets	$309.64M	$290.85M	$273.24M	$257.36M	$239.89M	$231.10M
Total Assets	$314.83M	$295.31M	$277.00M	$261.04M	$246.58M	$237.03M
Current Liabilities	$13.51M	$11.36M	$9.37M	$9.67M	$12.96M	$10.37M
Total Debt	$2.63M	$1.94M	$1.24M	$1.28M	$4.63M	$4.40M
Total Liabilities	$13.79M	$11.55M	$9.47M	$9.71M	$16.16M	$13.19M
Retained Earnings	-$164.49M	-$184.48M	-$203.51M	-$222.74M	-$247.98M	-$270.26M
Shareholders' Equity	$301.04M	$283.77M	$267.53M	$251.33M	$230.42M	$223.85M
Working Capital	$296.13M	$279.49M	$263.87M	$247.69M	$226.93M	$220.73M

TECX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$13.08M	-$14.72M	-$17.82M	-$14.46M	-$18.41M	-$21.45M
Capital Expenditure	-$27.00K	—	-$181.00K	—	-$19.00K	-$79.00K
Free Cash Flow	-$13.11M	-$14.72M	-$18.00M	-$14.46M	-$18.43M	-$21.53M
Depreciation & Amortisation	$360.00K	$340.00K	$342.00K	$333.00K	$304.00K	$285.00K
Stock-Based Compensation	$2.10M	$2.59M	$2.82M	$2.99M	$3.21M	$4.01M
Investing Cash Flow	-$27.00K	$55.00K	-$166.00K	$0.00	-$19.00K	-$59.00K
Financing Cash Flow	$178.12M	-$4.17M	-$457.00K	-$141.00K	$847.00K	$11.68M
Net Change in Cash	$165.01M	-$18.83M	-$18.44M	-$14.60M	-$17.59M	-$9.83M

Market Snapshot

About

Tectonic Therapeutic, Inc. is a biotechnology company focused on developing novel therapeutics targeting G protein-coupled receptors (GPCRs). The company uses its proprietary GEODe platform to discover and develop medicines for diseases with significant unmet medical needs. Tectonic is advancing a pipeline of drug candidates in oncology, inflammation, and metabolic diseases.